Case Study: Vyleesi™ (Bremelanotide Injection) for HSDD in Premenopausal Women
Posted on24 Jun 2019
Comments0
U.S. Food and Drug Administration (FDA) has approved Vyleesi™ (bremelanotide injection), a melanocortin receptor agonist, to treat acquired, generalized hypoactive sexual desire... Read More
AMAG Pharmaceuticals to Acquire Perosphere and Its Anticoagulant
Posted on17 Dec 2018
Comments0
AMAG Pharmaceuticals, Inc. will acquire Perosphere Inc. to leverage its expertise in hematology. The deal will provide the company the rights to... Read More
Takeda, Amag Terminate Ferumoxytol Accord for EU, Canada
Posted on01 Jan 2015
Comments0
Takeda Pharmaceutical and Amag Pharmaceuticals said today they “mutually” terminated their 2010 license, development, and commercialization agreement granting Takeda exclusive rights to... Read More